Andrea Apolo, MD, Oncology, Bethesda, MD, National Institutes of Health Clinical Center

AndreaBorgheseApoloMD

Oncology Bethesda, MD

Genitourinary Oncology, Hematologic Oncology

Chief, Bladder Cancer Section, Genitourinary Malignancies Branch Center for Cancer Research, National Cancer Institute, National Institutes of Health

Dr. Apolo is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Apolo's full profile

Already have an account?

Summary

  • Dr. Apolo is dedicated to improving the treatment and survival of patients with genitourinary tumors. Her research involves developing and designing clinical trials to test novel agents for the treatment of urologic cancers. Her primary research interest is in bladder cancer (urothelial carcinoma) and prostate cancer. In particular, she is working to develop new bladder cancer therapies that use targeted agents including anti-angiogenesis compounds, which block the growth of new blood vessels that feed tumors. Other research focuses include improving tumor detection by using new imaging modalities in bladder and prostate cancer and identifying molecular alterations in bladder tumors that will serve as targets for individualized treatment strategies in patients with this disease.

Education & Training

  • Memorial Sloan-Kettering Cancer Center
    Memorial Sloan-Kettering Cancer CenterFellowship, Hematology/Oncology, 2006 - 2009
  • New York Presbyterian Hospital
    New York Presbyterian HospitalResidency, Internal Medicine, 2003 - 2006
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineClass of 2003

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2006 - 2021

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNiv... 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • Immunotherapy and Coronavirus Vaccines, and a CT Scan
    Immunotherapy and Coronavirus Vaccines, and a CT ScanDecember 11, 2020 13:06
  • Choueiri Discusses Avelumab/Axitinib, Other Novel RCC Combos
    Choueiri Discusses Avelumab/Axitinib, Other Novel RCC CombosOctober 24, 2020 18:52
  • FDA Warns Against Single-Agent Checkpoint Inhibition for PD-L1-Low Untreated Urothelial Carcinoma
    FDA Warns Against Single-Agent Checkpoint Inhibition for PD-L1-Low Untreated Urothelial CarcinomaJune 27, 2020 09:50
  • Join now to see all

Hospital Affiliations